Assessment of Mortality Risk in Patients With Community-Acquired Pneumonia: Role of Novel Inflammatory Biomarkers

IF 2.9 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Journal of Clinical Laboratory Analysis Pub Date : 2025-08-13 DOI:10.1002/jcla.70081

Burcu Baran, Nur Aleyna Yetkin, Bilal Rabahoğlu, Nuri Tutar, İnci Gülmez

{"title":"Assessment of Mortality Risk in Patients With Community-Acquired Pneumonia: Role of Novel Inflammatory Biomarkers","authors":"Burcu Baran, Nur Aleyna Yetkin, Bilal Rabahoğlu, Nuri Tutar, İnci Gülmez","doi":"10.1002/jcla.70081","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Pneumonia is a lung parenchyma infection with clinical presentations ranging from mild to life-threatening. Its severity depends on factors such as the causative pathogen, the host's immune response, and existing comorbidities. This study aimed to investigate the prognostic value of novel inflammatory biomarkers for predicting in-hospital mortality in patients with community-acquired pneumonia (CAP).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective cross-sectional study included 207 hospitalized patients diagnosed with clinically and radiologically confirmed pneumonia. Laboratory data collected upon admission included complete blood count parameters, C-reactive protein (CRP), creatinine, and albumin levels. Systemic inflammatory biomarkers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CRP-to-albumin ratio (CAR), CRP-to-lymphocyte ratio (CLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), prognostic nutritional index (PNI), and C-reactive protein-albumin-lymphocyte (CALLY) index were calculated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The cohort was predominantly male (69%, <i>n</i> = 142) with a mean age of 62.1 ± 16.3 years. The median hospital stay was 8 days, with an 11% mortality rate. Malignancy was more frequent in the nonsurvivor group (<i>p</i> = 0.001). Nonsurvivors had significantly lower hemoglobin (<i>p</i> < 0.001) and albumin (<i>p</i> = 0.004) levels, while CRP (<i>p</i> = 0.024) and creatinine (<i>p</i> = 0.002) were elevated. NLR (<i>p</i> = 0.009), CAR (<i>p</i> = 0.011), CLR (<i>p</i> = 0.006), SII (<i>p</i> = 0.013), and SIRI (<i>p</i> = 0.024) were higher in nonsurvivors, while PNI (<i>p</i> = 0.010) and CALLY (<i>p</i> = 0.003) were lower.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Novel inflammatory biomarkers, particularly the CALLY index, are valuable for mortality prediction in CAP, aiding in risk stratification and early management.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"39 17","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.70081","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.70081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Pneumonia is a lung parenchyma infection with clinical presentations ranging from mild to life-threatening. Its severity depends on factors such as the causative pathogen, the host's immune response, and existing comorbidities. This study aimed to investigate the prognostic value of novel inflammatory biomarkers for predicting in-hospital mortality in patients with community-acquired pneumonia (CAP).

Methods

This retrospective cross-sectional study included 207 hospitalized patients diagnosed with clinically and radiologically confirmed pneumonia. Laboratory data collected upon admission included complete blood count parameters, C-reactive protein (CRP), creatinine, and albumin levels. Systemic inflammatory biomarkers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CRP-to-albumin ratio (CAR), CRP-to-lymphocyte ratio (CLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), prognostic nutritional index (PNI), and C-reactive protein-albumin-lymphocyte (CALLY) index were calculated.

Results

The cohort was predominantly male (69%, n = 142) with a mean age of 62.1 ± 16.3 years. The median hospital stay was 8 days, with an 11% mortality rate. Malignancy was more frequent in the nonsurvivor group (p = 0.001). Nonsurvivors had significantly lower hemoglobin (p < 0.001) and albumin (p = 0.004) levels, while CRP (p = 0.024) and creatinine (p = 0.002) were elevated. NLR (p = 0.009), CAR (p = 0.011), CLR (p = 0.006), SII (p = 0.013), and SIRI (p = 0.024) were higher in nonsurvivors, while PNI (p = 0.010) and CALLY (p = 0.003) were lower.

Conclusion

Novel inflammatory biomarkers, particularly the CALLY index, are valuable for mortality prediction in CAP, aiding in risk stratification and early management.

查看原文本刊更多论文

社区获得性肺炎患者死亡风险评估：新型炎症生物标志物的作用

背景：肺炎是一种肺实质感染，临床表现从轻微到危及生命不等。其严重程度取决于致病病原体、宿主免疫反应和现有合并症等因素。本研究旨在探讨新型炎症生物标志物在预测社区获得性肺炎（CAP）患者住院死亡率方面的预后价值。方法：本回顾性横断面研究纳入207例临床及影像学确诊的肺炎住院患者。入院时收集的实验室数据包括全血细胞计数参数、c反应蛋白（CRP）、肌酐和白蛋白水平。计算全身炎症生物标志物，如中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、crp与白蛋白比值（CAR）、crp与淋巴细胞比值（CLR）、全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）、预后营养指数（PNI）和c反应蛋白-白蛋白淋巴细胞（CALLY）指数。结果：该队列以男性为主（69%,n = 142），平均年龄为62.1±16.3岁。平均住院时间为8天，死亡率为11%。恶性肿瘤在非幸存者组中更为常见（p = 0.001）。结论：新的炎症生物标志物，特别是CALLY指数，对CAP的死亡率预测有价值，有助于风险分层和早期管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Laboratory Analysis 医学-医学实验技术

CiteScore

5.60

自引率

7.40%

发文量

584

审稿时长

6-12 weeks

期刊介绍： Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.